Current Affairs - Science - Discussion

Tentative approval was granted by the U.S. Food and Drug Administration for a generic version of Erdafitinib in multiple strengths, expanding access to an important cancer treatment in the US market. Natco Pharma secured this approval for the drug equivalent to Janssen’s Balversa. Erdafitinib is prescribed for adults with unresectable or metastatic urothelial carcinoma that carries specific FGFR3 genetic alterations. This development highlights Natco Pharma’s growing presence in the oncology segment and reflects its focus on making advanced cancer therapies more affordable and accessible to patients through high-quality generic medicines.